Clinical Trial Update: Carbidopa-Levodopa (CD-LD) ER Alone or in Combination With CD-LD IR to IPX066 Followed by IPX066 Extension Safety Study [Phase 3]

View source ↗

Summary

Phase 3 trial update comparing carbidopa-levodopa extended-release alone or with immediate-release in IPX066 follow-up and a safety extension study for Parkinso…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Carbidopa-levodopa ER (carbidopa-levodopa extended-release)
• IPX066 (carbidopa-levodopa formulation)

Snippet

Sponsor: Impax Laboratories, LLC | Conditions: Parkinson's Disease | Phase 3 | Status: COMPLETED | Results posted: 2017-04-18